Background: Humanized mice represent a relatively recent tool in the growing armamentarium of animal models for the in vivo study of HIV and other human hematotropic viruses. These models can be created by transplanting human hematopoietic cells into immunodeficient mice. However, the choice of mouse strain used can have dramatic effects on the reconstitution of key immune organs like the gut. Another important, issue that affects reconstitution and outcomes is the co-implantation of human thymus, used in the bone marrow/liver/thymus (or BLT) model, which can result in bona fide education of human T cells in the context of HLA. Highly relevant to in vivo studies of HIV persistency has been the development and implementation of adequate drug regimens that can suppress peripheral blood viremia. This has been achieved in mouse models using the same antiretrovirals used in humans. Also critical to these efforts, has been the establishment of sensitive and reproducible assays for latency in human T cells obtained from these mice. This has been recently demonstrated in mouse models using the same methodology used to quantitate the number of latently infected cells present in the peripheral blood of humans. Based on this information, BLT humanized mice have more recently been used to establish the systemic distribution of latently infected cells in vivo and to evaluate novel approaches to destroy residual HIV+ cells in tissues. Specifically, we used BLT humanized mice to evaluate the efficacy of envelope targeted immunotoxins to kill HIV infected cells in the tissues of ART suppressed mice. Conclusions: Our results demonstrate that this approach can be highly effective at killing residual HIV infected cells in vivo. In summary, humanized BLT mice serve as a flexible and accessible platform for the in vivo evaluation of novel approaches for the study of HIV latency, reservoirs and eradication strategies.